MI Cancer Seek™ is the first FDA-approved test combining whole exome and transcriptome sequencing for solid tumor molecular profiling. The test identifies patients for targeted therapies in breast, ...
DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics, a pioneer in single-cell and ultra-low input multiomics is excited to announce the launch of ResolveSEQ MRD, an innovative service offering designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results